TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04756934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008: 200mg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008: 200mg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008: 200mg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008: 200mg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
Study: NCT03372525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOV
Description: Infants were randomized to HFOV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMV
Description: Infants were randomized to CMV
Study: NCT00123084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice/Respiration Treatment
Description: Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech/Articulation Treatment
Description: Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
Study: NCT01976988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
Study: NCT01983930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory Training
Description: Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
Study: NCT03647839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC 105
Description: BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
Study: NCT02344810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: c-Met inhibitor AMG 337
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT03647839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
Study: NCT02344810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study: NCT03810950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: Test to induce high levels of acute social stress, including actors and a faked exam situation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Newspaper
Description: Participants read newspaper

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Barlab-Exposure
Description: Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
Study: NCT01976988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
Study: NCT04037878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block(TAP Block)
Description: Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
Study: NCT03810950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barlab-Exposure
Description: Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
Study: NCT00993122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin pre-treatment
Description: patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin pre-treatment
Description: patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
Study: NCT02128997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed incision wound vacuum (Prevena)
Description: wound vacuum to be placed on a closed incision
Study: NCT02576522

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brain metastatic patients
Description: Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
Study: NCT00327379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
Study: NCT04037878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-peritoneal infiltration
Description: Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine

Intervention type: DRUG
Group type: OTHER
Intervention: PCIA Tramadol
Description: All patients will be given patient controlled intravenous analgesia using Tramadol as the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCIA Tramadol
Description: All patients will be given patient controlled intravenous analgesia using Tramadol as the drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCIA Tramadol
Description: All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
Study: NCT01535976

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo~.9 normal saline infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
Study: NCT04691947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERUCOV-VAC
Description: Vaccination on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERUCOV-VAC
Description: Vaccination on Day 0 and Day 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo Vaccination on Day 0 and Day 21
Study: NCT00879931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (NaCl 0.9%)
Study: NCT04425044

Intervention type: OTHER
Intervention: Other
Description: No Intervention
Study: NCT03252600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00355641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Extended Release (XR)
Description: Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
Study: NCT00784875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: 1 mg, oral capsule, once nightly before bedtime
Study: NCT01400438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: delivery of questionnaires and self-psychological interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: delivery of questionnaires and self-psychological interview
Study: NCT02265601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-based decision aid
Description: Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: paper/pencil living will form
Study: NCT02480725

Intervention type: PROCEDURE
Intervention: collect CSF (Cerebrospinal fluid) sample
Description: collecting CSF samples for thrombin activity assay
Study: NCT03723603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibrillar collagen powder dressing
Description: A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
Study: NCT00872625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT00784875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: 1 mg, oral capsule, once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: 1 mg, oral capsule, once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: 3 mg, oral capsule, once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: 3 mg, oral capsule, once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: 3 mg, oral capsule, once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo (capsule or tablet), once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo (capsule or tablet), once nightly before bedtime
Study: NCT02344810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01213056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: Cognitive Behavioral (Active treatment condition)
Study: NCT00843180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
Study: NCT00784875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo (capsule or tablet), once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo (capsule or tablet), once nightly before bedtime
Study: NCT00327379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
Study: NCT04123808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IpsiHand Treatment
Description: The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
Study: NCT03097887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omega Loop Gastric Bypass
Description: Bariatric/metabolic surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omega Loop Gastric Bypass
Description: Bariatric/metabolic surgical procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilitec 2000™
Description: The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilitec 2000™
Description: The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Loc
Description: Sewing device to perform the anti-reflux sutures.
Study: NCT00477087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
Study: NCT01969747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin medium placebo
Description: Empagliflozin medium placebo
Study: NCT01640847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
Study: NCT01969747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low placebo
Description: Empagliflozin low placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin low placebo
Description: Empagliflozin low placebo
Study: NCT00784875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: 5 or 10 mg, oral tablet, once nightly before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: 5 or 10 mg, oral tablet, once nightly before bedtime
Study: NCT01969747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high placebo
Description: Empagliflozin high placebo
Study: NCT00260130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food in fluid form
Description: dietary intake of fluid forms of vegetables

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food in solid form
Description: dietary intake of solid forms of vegetables
Study: NCT04132050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R788
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R788
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT01969747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin medium
Description: Empagliflozin medium
Study: NCT01954823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-diary
Description: The e-diary can collect data on:~* Medical data: information on diseases, treatments and attending physicians~* Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~* Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~* Reports: textual and graphical reports of the data in the diary can be created
Study: NCT01564784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
Study: NCT01564784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAG (fludarabine, cytarabine and G-CSF)
Description: Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIDAC (high dose cytarabine)
Description: cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine and mitoxantrone
Description: mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
Study: NCT03315429

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: stress echocardiography
Description: stress testing of patients with functional mitral regurgitation
Study: NCT00397150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-support for exclusive breastfeeding
Description: Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
Study: NCT01446211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gusperimus + glucocorticoids
Description: Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
Study: NCT01969747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high placebo
Description: Empagliflozin high placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin high placebo
Description: Empagliflozin high placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin medium placebo
Description: Empagliflozin medium placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low placebo
Description: Empagliflozin low placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low
Description: Empagliflozin low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high
Description: Empagliflozin high
Study: NCT03126747

Intervention type: DRUG
Intervention: BAY86-5300_YAZ-Flex
Description: Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
Study: NCT02251886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion in primiparae
Description: Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion in multiparae
Description: Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
Study: NCT00784875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: 5 or 10 mg, oral tablet, once nightly before bedtime
Study: NCT00673647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: 10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
Study: NCT02371486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic repair of cesarean section defect
Description: Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Hysteroscopy
Description: Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Diagnostic Hysteroscopy
Description: Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.